Citigroup started coverage on shares of BioNTech (NASDAQ:BNTX – Free Report) in a report issued on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $145.00 target ...
Analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of BioNTech in a research report ...
BioNTech SE ( NASDAQ:BNTX ) just released its full-year report and things are looking bullish. Results overall ...
Q4 2024 Earnings Call Transcript March 10, 2025 Operator: Welcome to BioNTech’s Fourth Quarter and Full-Year 2024 Earnings ...
这家德国生物科技公司第四季度每股收益达到€1.08,超过分析师预期。营收为€11.9亿,高于€11.2亿的市场预期。 2024财年,BioNTech录得净亏损€6.653亿,即每股亏损€2.77,而2023年同期为净利润€9.303亿,每股收益€3.83。全年营收从上年的€38.2亿下降至€27.5亿。
周一,Jefferies重申了对BioNTech SE(NASDAQ:BNTX)的股票评级和目标价,维持买入评级,目标价为149.00美元。此次重申是在该公司最新季度财报发布后做出的。财报显示,公司收入约为11.9亿欧元,略高于市场预期的11.8亿欧元。得益于运营支出的降低,每股收益(EPS)达到1.08欧元,同样超过了市场预期的0.77欧元。根据 InvestingPro ...
In the last three months, 4 analysts have published ratings on BioNTech (NASDAQ:BNTX), offering a diverse range of perspectives from bullish to bearish. In the table below, you'll find a summary ...
BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.
BioNTech (NasdaqGS:BNTX) reported a 2.49% weekly price decline following its announcement of diminished Q4 2024 earnings, where sales and net income significantly dropped compared to the previous year ...
Shares of German biotech BioNTech (Nasdaq: BNTX) dipped 2.5% to $105.86 today, after it reported financial results for the ...
In a report released today, Eliana Merle from UBS maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target of ...